Methodological evaluation of the noninvasive estimation of central systolic blood pressure in nontreated patients: the Bogalusa Heart Study.
Camilo Fernandez, Robert Hsu, Gary Sander, Azad Hussain, Rupert Barshop, Shengxu Li, Tian Shu, Tao Zhang, Patrycja Galazka, Wei Chen, Lydia Bazzano, Thomas D Giles
Author Information
Camilo Fernandez: aDepartment of Epidemiology, Tulane University School of Public Health and Tropical Medicine bHeart and Vascular Institute, Tulane University School of Medicine, New Orleans, Louisiana cHeartGEN Institute dHeart and Vascular Center, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
OBJECTIVES: This study sought to compare the estimation of central systolic blood pressure (cSBP) obtained by two different noninvasive devices, in addition to its comparisons with measured peripheral systolic blood pressure (pSBP), in a biracial (Black/White) community-based cohort. PARTICIPANTS AND METHODS: Estimations of cSBP by applanation tonometry were obtained in 586 participants of the Bogalusa Heart Study (mean age: 43.5 years; 69% White, 54% women) using two different commonly used instruments: Omron HEM-9000AI and SphygmoCor CPV. pSBP was measured using a standard auscultatory technique. RESULTS: The estimation of cSBP by the Omron device was higher than that of the SphygmoCor device (124.2±17.1 vs. 111.4±15.2 mmHg, P<0.001). Moreover, cSBP by Omron was significantly higher than peripheral blood pressure (124.2±17.1 vs. 119.4±15.6 mmHg, P<0.001), whereas cSBP by SphygmoCor was significantly lower than pSBP (111.4±15.2 vs. 119.4±15.6 mmHg, P<0.001). Similar results were observed in race-specific and sex-specific analyses. CONCLUSION: These findings support the hypothesis that notable differences exist in the estimation of cSBP provided by the instruments utilized in this study. Further standardization studies are required to establish the most appropriate noninvasive estimation of cSBP before this parameter may be considered in the assessment, prediction, and prevention of cardio-metabolic risk and overt cardiovascular disease in clinical practice.
